Future research may benefit from both analyzing and improving current decision making processes. Photo via Getty Images

Real options represent the decisions companies can make in the face of evolving risk. In the energy and commodity industries, real options are ubiquitous, including the extraction, processing and refinement, storage, and transportation of natural resources. These choices are influenced by ever-changing market and environmental conditions.

Because of these uncertainties, the energy industry has been a key focus of the operations literature on real options. Rice Business professor Nicola Secomandi, along with University of Illinois at Chicago College of Business Administration professor Selvaprabu Nadajarah, were recently invited by the European Journal of Operational Research to conduct a review of the operations literature on real options in energy. Their review included 80 papers across 10 journals active in the field. The research was mostly conducted during Secomandi’s time at the Tepper School of Business at Carnegie Mellon University.

The review examined how often different types of energy and methods of studying related business processes appeared in the operations literature. Nearly a quarter of the papers considered natural gas, more often than any other energy type. Natural gas storage was the most studied process, while the transport and sale of natural gas were less discussed.

While only 10 percent of the papers focused on electricity by itself, mostly in the context of battery management, electricity was discussed alongside emissions and the environment in 22.5 percent of the papers—almost as often as natural gas. About 11 percent of the papers examined both electricity and natural gas.

Roughly 21 percent of the papers focused on crude oil and refined products. Exploration, development, and abandonment of crude oil fields were common topics, while work on crude oil refining and gasoline logistics was rarer.

The review looked at the frequency of use of five categories: real option types, valuation methodologies, model formulations, price risk dynamics, and optimization schemes. Timing options, which irreversibly change the status of an asset when exercised, and switching options, which involve reversible changes, appeared with about equal frequency. Of the valuation methodologies, risk neutral valuation was employed the most often, appearing in nearly 78 percent of the papers. Model formulations were divided mainly between Markov decision processes, which assume that decisions are made at set times, and stochastic optimal control models, which assume that decisions are made continuously. About 63 percent of the papers discussed Markov decision processes, but at nearly 34 percent, stochastic optimal control models haven’t been entirely left out of the literature. Almost 75 percent of the papers formulated models based on spot prices as opposed to futures prices, and over 80 percent adopted normal distribution models, either alone or in combination with other models. Approximate solution approaches dominated within optimization schemes, appearing in 71 percent of the papers.

While several energy sources and analysis tools have been discussed in the literature, the possibilities for future research remain broad. The transition to clean energy sources may increase the complexity of already intricate operations. Its modeling and analysis may require more advanced models than existing ones.

------

This article originally ran on Rice Business Wisdom and was based on research from Nicola Secomandi, the Houston Endowment Professor of Management – Operations Management at Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."